Authors
Latest:
Pharma’s Business Case for RWE: Tapping the Full Value From These InsightsHow drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.
Latest:
A Culture of Quality: The Catalyst to Accelerate InnovationWhy enabling a shared culture of quality across an organization is key to maintaining pharma’s recent pace of innovation wins—while inspiring new levels of confidence.
Latest:
The Real Cost of State Drug Importation Programs? Patient SafetyImporting drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.
Latest:
From Potential to Value: Carving a Slice of the CGT ‘PIE'The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.
Latest:
Three Keys to Ireland’s Resilient Pharma IndustryRecent growth in pharma makes Ireland an ideal candidate for expansion opportunities.
Latest:
The Resilience of R&D: Pharma Posted Record Output in 2021Despite disruption from the COVID-19 pandemic still in full swing, life sciences innovation activity remained undeterred, a recent report from the IQVIA Institute for Human Data Science finds—outlining the key factors driving record-breaking growth.
Latest:
Recent Federal Circuit Developments in Patent LicensingUnderstanding of recent legal developments can help companies avoid infringement.
Latest:
With Project Optimus, Success Favors the PreparedOncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.
Latest:
Achieving Diverse Teams for a Diverse WorldThe benefits of diversity in the workplace are far-reaching — not just for employees, but for a company’s overall health.
Latest:
Say Hello to Flexible: Reimagining the Patient JourneyThrough embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.
Latest:
Cold Chain: Delivering Innovative Specialty Pharmaceutical ProductsRafael Teixeira on building an end-to-end cold chain strategy to support global storage and distribution efforts.
Latest:
Doing More With Less: How Automation is Reshaping Drug SafetyBetter technology is redefining pharmacovigilance as it expands beyond its traditional compliance focus to become a key business differentiator.
Latest:
Final ThoughtsThe future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Latest:
How to Rally a Team Around Building a New BusinessThree key components to scaling quickly—while maintaining purpose.
Latest:
Optimizing Pharma Content for Faster Product SubmissionsPharma and life science companies can reduce time to market by optimizing regulatory content management and submission processes.
Latest:
Why Healthcare Costs are Surging—And What to Do About itIdentifying the inflators and deflators, and the role all stakeholders play.
Latest:
Pharma’s Remote Work Cybersecurity ChallengeThe massive shift to remote work has seen pharma companies increasingly targeted by malicious actors seeking out weaker points across the business ecosystem. But with the right mix of technology and mindset, organizations can prepare against threats in the future.
Latest:
Final ThoughtsThe future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Biotech Companies Deal with Silicon Valley Bank CollapseSilicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.
Latest:
A Rare-Disease Must? Building Long-Term RelationshipsThe importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.
Latest:
All in on AI is Not the Solution in Life Sciences and Health CareAlthough life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.
Latest:
In life sciences, the metaverse opportunity knocksHere are three mindsets for pharma companies to adopt now to reap the rewards of early action in the metaverse.
Latest:
Three Ways Life Sciences Can Educate Stakeholders About BiosimilarsThere are several strategies life sciences companies can use to benefit from biosimilars.
Latest:
Moving Beyond Traditional Approaches to Alzheimer’s DiseaseThe recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.
